REFRACTORY MULTIPLE MYELOMA
Clinical trials for REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Supercharged immune cells take on Hard-to-Treat myeloma
Disease control CompletedThis early-phase study tests a new treatment for multiple myeloma that has returned or stopped responding to prior therapies. It combines specially engineered natural killer (NK) cells (called TiNK) with an antibody drug (isatuximab) and standard chemotherapy. The main goal is to…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Elvira Umyarova • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
New hope for Tough-to-Treat myeloma: experimental drug shows promise
Disease control CompletedThis study tested a new drug called REGN5459 in 43 people with multiple myeloma that had returned or stopped responding to other treatments. The drug works by helping the immune system attack cancer cells. The main goals were to check safety and find the best dose, and to see how…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug shows promise for Hard-to-Treat blood cancer
Disease control CompletedThis study tested a drug called elranatamab in 39 Chinese patients with multiple myeloma that had stopped responding to at least three prior treatments. The drug works by helping the immune system attack cancer cells. The goal was to see if it could shrink tumors and control the …
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug cocktail shows early promise for Hard-to-Treat myeloma
Disease control CompletedThis early-phase study tested a combination of three drugs—ibrutinib, lenalidomide, and dexamethasone—in 14 people with multiple myeloma that had come back or stopped responding to prior treatments. The main goal was to find safe doses and watch for side effects. Results help gui…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug cocktail shows promise for Hard-to-Treat myeloma
Disease control CompletedThis early-phase trial tested a combination of three drugs—selinexor, carfilzomib, and dexamethasone—in 52 patients with multiple myeloma that had returned or stopped responding to treatment. The main goal was to find the safest dose and check for side effects. Researchers hope t…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug cocktail shows promise for Hard-to-Treat myeloma
Disease control CompletedThis study tested a combination of three drugs (pomalidomide, ixazomib, and dexamethasone) with or without a fourth drug (cyclophosphamide) in 66 adults with multiple myeloma that had come back or stopped responding to treatment. The goal was to see how well the treatment control…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Stem cell transplant or drug combo: which works better for myeloma?
Disease control CompletedThis study tested two ways to treat multiple myeloma that has come back or stopped responding to treatment. All 23 participants first received a combination of clarithromycin, pomalidomide, and dexamethasone. Then, half got a stem cell transplant followed by pomalidomide, while t…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 16:52 UTC